Shots: The P-III study involves assessing CT-P17 (40mg, q2w) vs reference adalimumab for up to 24wks. in 648 patients with active moderate-to-severe RA despite MTX treatment Results demonstrated that CT-P17 […]readmore
Tags : RA
Shots: The P-III FINCH-3 study involves assessing of filgotinib (100/200 mg) + methotrexate (MTX) vs filgotinib (200mg)/MTX as monothx in 1252 patients in ratio (2:1:1:2) with moderate to severe active […]readmore
Shots: The approval is based on global P-III trial results assessing etanercept biosimilar (YLB113) vs Enbrel in 500 patients with RA across 11 countries including Japan, EU and India, evaluating […]readmore
Shots: The approval is based on P-I & P-IV study assessing Actemra 162 mg SC via the pre-filled syringe (PFS) vs Actemra 162 mg SC via the ACTPen & testing […]readmore
Shots: FINCH-2 trial assessing filgotinib administering qd (200/100mg) vs PBO in ratio (1:1:1) for 24 wks. in moderate-to-severe active RA patients, intolerant to bDMARDs FINCH-2 results (N= ≥153): ACR20@12wk (66 […]readmore
Regulatory
Eli Lilly’s Olumiant (baricitinib) Receives FDA Approval for Moderately-to-Severely Active
Shots: The approval is based on P-III RA-BEACON study results assessing Olumiant vs PBO in 527 patients with inadequate response or intolerance to one or more TNF inhibitor therapies P-III […]readmore